Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE).

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-27
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.5034
Primary Topic
Genital Health and Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE).

Fang Yuan
Journal of Clinical Oncology
Genital Health and Disease
article

Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE).

Fang Yuan
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 44(16_suppl)
Chongqing University (CN), Chongqing Cancer Hospital (CN)
Good health and well-being
Openalex Percentile: Top 5%
Genital Health and Disease
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of disitamab vedotin combined with toripalimab for cisplatin-refractory advanced penile cancer: A prospective single-center study (SAVE). — Fang Yuan · Journal of Clinical Oncology (2026) | TGRS Research Map | TGRS